Differential expression of two activating transcription factor 5 isoforms in papillary thyroid carcinoma
Authors Vicari L, La Rosa C, Forte S, Calabrese G, Colarossi C, Aiello E, Salluzzo S, Memeo L
Received 19 May 2016
Accepted for publication 3 July 2016
Published 11 October 2016 Volume 2016:9 Pages 6225—6231
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Akshita Wason
Peer reviewer comments 2
Editor who approved publication: Dr William Cho
Luisa Vicari,1,* Cristina La Rosa,2,3,* Stefano Forte,1 Giovanna Calabrese,1 Cristina Colarossi,2 Eleonora Aiello,2 Salvatore Salluzzo,2 Lorenzo Memeo1,2
1IOM Ricerca srl, Viagrande CT, Italy; 2Department of Experimental Oncology, Istituto Oncologico del Mediterraneo, Viagrande CT, Italy; 3Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Roma, Italy
*These authors contributed equally to this work
Background: Activating transcription factor 5 (ATF5) is a member of the activating transcription/cAMP response element-binding protein family of basic leucine zipper proteins that plays an important role in cell survival, differentiation, proliferation, and apoptosis. The ATF5 gene generates two transcripts: ATF5 isoform 1 and ATF5 isoform 2. A number of studies indicate that ATF5 could be an attractive target for therapeutic intervention in several tumor types; however, so far, the role of ATF5 has not been investigated in papillary thyroid carcinoma (PTC).
Methods: Quantitative real-time reverse transcription polymerase chain reaction and immunohistochemical staining were used to study ATF5 mRNA and protein expression in PTC.
Results: We report here that ATF5 is expressed more in PTC tissue than in normal thyroid tissue. Furthermore, this is the first study that describes the presence of both ATF5 isoforms in PTC.
Conclusion: These findings could provide potential applications in PTC cancer treatment.
Keywords: papillary thyroid carcinoma, ATF5, therapeutic target, qRT-PCR, IHC
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]